Literature DB >> 33537874

Talin1 Induces Epithelial-Mesenchymal Transition to Facilitate Endometrial Cell Migration and Invasion in Adenomyosis Under the Regulation of microRNA-145-5p.

Yi-Yi Wang1, Hua Duan2, Sha Wang1, Yong-Jun Quan3, Jun-Hua Huang1, Zheng-Chen Guo1.   

Abstract

Adenomyosis (ADS) is a commonly encountered benign gynecological disorder. Epithelial-mesenchymal transition (EMT) may serve a pivotal role in the pathogenesis of ADS. Talin1 has been identified to be implicated in multiple human carcinomas, probably through inducing EMT process. However, available data on the precise molecular mechanism of Talin1 in the pathogenesis of ADS remain extremely scanty. In the present study, we aim to investigate the clinical roles of Talin1 and its effects on uterine endometrial cell migration, invasion, and EMT in ADS. Relative mRNA expression of Talin1, microRNA-145-5p (miR-145-5p), and EMT-related markers was determined by qRT-PCR. Immunohistochemistry and immunofluorescence were performed to examine the distribution of Talin1 in ADS endometrium. Protein levels of Talin1, EMT-related markers, and wnt/β-catenin pathway were measured by western blot. Wound healing assay and transwell assay were utilized for evaluating cell migration and invasion respectively. Dual-luciferase reporter assay was performed to verify the relationship between Talin1 and miR-145-5p. We found Talin1 was markedly overexpressed in ADS endometrial tissue and cells, whereas miR-145-5p was downregulated. Elevated Talin1 mRNA level might be closely related to some clinicopathological features of ADS. Through functional experiments, we demonstrated that overexpression of Talin1 induced EMT and enhanced migration and invasion ability of ADS eutopic and ectopic endometrial epithelial cells (ADS_Eu_EEC and ADS_Ec_EEC) in vitro through activating the canonical wnt/β-catenin pathway. From a mechanistic perspective, Talin1 was inversely regulated by miR-145-5p as a direct target. Our findings unveiled that under the regulation of miR-145-5p, Talin1 might promote endometrial cell migration and invasion through inducing EMT, presenting a novel insight for elucidating the pathogenesis of ADS.

Entities:  

Keywords:  Adenomyosis (ADS); Adenomyotic eutopic and ectopic endometrial epithelial cells (ADS_Eu_EEC and ADS_Ec_EEC); Epithelial-mesenchymal transition (EMT); Invasion; Migration; Talin1; miR-145-5p

Mesh:

Substances:

Year:  2021        PMID: 33537874     DOI: 10.1007/s43032-020-00444-8

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  46 in total

Review 1.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

2.  Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis.

Authors:  Xishi Liu; Minhong Shen; Qiuming Qi; Hongqi Zhang; Sun-Wei Guo
Journal:  Hum Reprod       Date:  2016-02-22       Impact factor: 6.918

3.  Introduction: Uterine adenomyosis, another enigmatic disease of our time.

Authors:  Jacques Donnez; Olivier Donnez; Marie-Madeleine Dolmans
Journal:  Fertil Steril       Date:  2018-03-08       Impact factor: 7.329

4.  EMT in cancer.

Authors:  Thomas Brabletz; Raghu Kalluri; M Angela Nieto; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

5.  Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis.

Authors:  Yi-Jen Chen; Hsin-Yang Li; Chi-Hung Huang; Nae-Fang Twu; Ming-Shyen Yen; Peng-Hui Wang; Teh-Ying Chou; Yen-Ni Liu; Kuan-Chong Chao; Muh-Hwa Yang
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

Review 6.  Pathogenesis of uterine adenomyosis: invagination or metaplasia?

Authors:  Javier García-Solares; Jacques Donnez; Olivier Donnez; Marie-Madeleine Dolmans
Journal:  Fertil Steril       Date:  2018-03       Impact factor: 7.329

Review 7.  Structural and molecular features of the endomyometrium in endometriosis and adenomyosis.

Authors:  Giuseppe Benagiano; Ivo Brosens; Marwan Habiba
Journal:  Hum Reprod Update       Date:  2013-10-18       Impact factor: 15.610

8.  β-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition.

Authors:  Seo Jin Oh; Jung-Ho Shin; Tae Hoon Kim; Hee Sun Lee; Jung-Yoon Yoo; Ji Yeon Ahn; Russell R Broaddus; Makoto M Taketo; John P Lydon; Richard E Leach; Bruce A Lessey; Asgerally T Fazleabas; Jeong Mook Lim; Jae-Wook Jeong
Journal:  J Pathol       Date:  2013-10       Impact factor: 7.996

Review 9.  The tale of two talins - two isoforms to fine-tune integrin signalling.

Authors:  Rosemarie E Gough; Benjamin T Goult
Journal:  FEBS Lett       Date:  2018-05-18       Impact factor: 4.124

10.  Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis.

Authors:  Xue Shen; Hua Duan; Sha Wang; Lu Gan; Qian Xu; Jin-Jiao Li
Journal:  Biomed Res Int       Date:  2019-01-20       Impact factor: 3.411

View more
  3 in total

1.  Estrogen-increased SGK1 Promotes Endometrial Stromal Cell Invasion in Adenomyosis by Regulating with LPAR2.

Authors:  Guangzheng Zhong; Qingxue Zhang; Yingchen Wu; Hao Wang; Yi Li; Yangzhi Li; Yihua Liang
Journal:  Reprod Sci       Date:  2022-07-07       Impact factor: 2.924

2.  Upregulated Talin1 synergistically boosts β-estradiol-induced proliferation and pro-angiogenesis of eutopic and ectopic endometrial stromal cells in adenomyosis.

Authors:  Yi-Yi Wang; Hua Duan; Sha Wang; Yong-Jun Quan; Jun-Hua Huang; Zheng-Chen Guo
Journal:  Reprod Biol Endocrinol       Date:  2021-05-14       Impact factor: 5.211

Review 3.  Unveiling the Pathogenesis of Adenomyosis through Animal Models.

Authors:  Xi Wang; Giuseppe Benagiano; Xishi Liu; Sun-Wei Guo
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.